Sanofi signed a $1.2B biobucks AI drug-discovery research collaboration with Atomwise. Sanofi paid $20M upfront with up to $1B in research, development and sales milestones plus tiered royalties. Atomwise's AtomNet platform applies deep learning to a 3-trillion-compound library to identify small-molecule candidates against up to five undisclosed targets.
Key facts
AnnouncedAug 15, 2022
Deal value$1.0B
Deal typeCo-Development
Therapeutic areaMultiple (undisclosed)
IndicationsMultiple (undisclosed)
Key assetsAI-discovered small molecules (up to 5 targets)
MechanismAtomNet AI-driven structure-based small-molecule drug discovery